Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab

Medical Oncology

Volumn 27, Issue 3, 2010, Pages 807-814

  Suenaga, Mitsukuni ^a   Mizunuma, Nobuyuki ^a   Kobayashi, Kokoro ^a   Shinozaki, Eiji ^a   Matsusaka, Satoshi ^a   Chin, Keisho ^a   Kuboki, Yasutoshi ^a   Ichimura, Takashi ^a   Ozaka, Masato ^a   Ogura, Mariko ^a   Fujiwara, Yoshimasa ^a   Matsueda, Kiyoshi ^a   Konishi, Fumio ^b   Hatake, Kiyohiko ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Bevacizumab; Colorectal cancer; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CATHETER THROMBOSIS; CLINICAL ARTICLE; COLORECTAL CANCER; DIAGNOSTIC IMAGING; DOPPLER ECHOGRAPHY; DRUG EFFECT; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LUNG EMBOLISM; MALE; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CATHETERIZATION, CENTRAL VENOUS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RISK FACTORS; THROMBOPHILIA; ULTRASONOGRAPHY, DOPPLER; VENA CAVA, SUPERIOR; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 77956910426     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9289-6     Document Type: Article

References (31)

1. FF Kabbinavar, et al. 2005 Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 3697 3705 10.1200/JCO.2005.05.112 15738537 1:CAS:528:DC%2BD2MXlslWntr0%3D
2. F Kabbinavar, et al. 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60 65 10.1200/JCO.2003.10.066 12506171 1:CAS:528:DC%2BD2cXpsVWru7Y%3D
3. H Hurwitz, et al. 2004 Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 15175435 1:CAS:528:DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
4. BJ Giantonio, et al. 2007 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539 1544 10.1200/JCO.2006.09.6305 17442997 1:CAS:528:DC%2BD2sXlsVyntbc%3D (Pubitemid 46733080)
5. A Grothey, et al. 2007 Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE) J Clin Oncol 25 June 20 Supplement 4036 (Abstract)
6. FA Scappaticci, et al. 2007 Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 1232 1239 10.1093/jnci/djm086 17686822 (Pubitemid 47299901)
7. SR Nalluri D Chu R Keresztes X Zhu S Wu 2008 Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 19 2277 2285 10.1001/jama.2008.656 19017914 1:CAS:528:DC%2BD1cXhtlyrt77O
8. AY Lee, et al. 2006 Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer J Clin Oncol 24 1404 1408 10.1200/JCO.2005.03.5600 16549834 (Pubitemid 46622005)
9. M Verso G Agnelli 2003 Venous thromboembolism associated with long-term use of central venous catheters in cancer patients J Clin Oncol 21 3665 3675 10.1200/JCO.2003.08.008 14512399 (Pubitemid 46594061)
10. M Montréal, et al. 1994 Pulmonary embolism in patients with upper extremity DVT associated to venous central lines: a prospective study Thromb Haemost 72 548 550
11. D Fagnani, et al. 2007 Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis Ann Oncol 18 551 555 10.1093/annonc/mdl431 17158773 1:STN:280:DC%2BD2szlt1Wquw%3D%3D (Pubitemid 46359638)
12. S Couban, et al. 2005 Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer J Clin Oncol 23 4063 4069 10.1200/JCO.2005.10.192 15767639 1:CAS:528:DC%2BD2MXmt1emurY%3D (Pubitemid 46211311)
13. M Karthaus, et al. 2006 Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial Ann Oncol 17 289 296 10.1093/annonc/mdj059 16317012 1:STN:280:DC%2BD28%2FjvVGksg%3D%3D (Pubitemid 43160120)
14. AA Khorana CW Francis E Culakova NM Kuderer GH Lyman 2007 American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer J Clin Oncol 25 5490 5505 10.1200/JCO.2007.14.1283 17968019 1:CAS:528:DC%2BD1cXnvVChtA%3D%3D (Pubitemid 350232226)
15. AA Khorana CW Francis E Culakova 2007 Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy J Thromb Haemost 5 632 634 10.1111/j.1538-7836.2007.02374.x 17319909 1:STN:280: DC%2BD2s7itFCrtQ%3D%3D (Pubitemid 46680709)
16. JA Heit, et al. 2000 Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch Intern Med 160 809 815 10.1001/archinte.160.6.809 10737280 1:STN:280:DC%2BD3c7pvFGnsw%3D%3D
17. KD Miller, et al. 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792 799 10.1200/JCO.2005.05.098 15681523 1:CAS:528:DC%2BD2MXitVKitrk%3D (Pubitemid 46224178)
18. DH Johnson, et al. 2004 Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2184 2191 10.1200/JCO.2004.11.022 15169807 1:CAS:528: DC%2BD2cXpsVWltrg%3D (Pubitemid 41095154)
19. S Vescia, et al. 2008 Management of venous port systems in oncology: a review of current evidence Ann Oncol 19 9 15 10.1093/annonc/mdm272 17846025 1:STN:280:DC%2BD1c%2FgtVantw%3D%3D
20. KA Newman WP Reed SC Schimpff CI Bustamante JC Wade 1993 Hickman catheters in association with intensive cancer chemotherapy Support Care Cancer 1 92 97 10.1007/BF00366902 8143107 1:STN:280:DyaK2c7ptF2msA%3D%3D
21. PE Drakos, et al. 1992 Low molecular weight heparin for Hickman catheter-induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation Cancer 70 1895 1898 10.1002/1097-0142(19921001)70:7<1895:: AID-CNCR2820700715>3.0.CO;2-I 1326397 1:STN:280:DyaK38vgsFSktA%3D%3D
22. JJ Lokich B Becker 1983 Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy Cancer 52 1586 1589 10.1002/1097-0142(19831101)52:9<1586::AID-CNCR2820520908>3.0.CO;2-4 6616416 1:STN:280:DyaL2c%2FgtFygsQ%3D%3D
23. C Koksoy A Kuzu I Erden A Akkaya 1995 The risk factors in central venous catheter-related thrombosis Aust NZ J Surg 65 796 798 10.1111/j.1445-2197.1995. tb00563.x 1:STN:280:DyaK28%2Fks1KgsQ%3D%3D
24. A Cortelezzi, et al. 2005 Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective, multicenter study Br J Haematol 129 811 817 10.1111/j.1365-2141. 2005.05529.x 15953009 (Pubitemid 40904533)
25. M Verso, et al. 2005 Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients J Clin Oncol 23 4057 4062 10.1200/JCO.2005.06.084 15767643 1:CAS:528:DC%2BD2MXmt1emurg%3D (Pubitemid 46211310)
26. Berry S et al. Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing/bleeding complications: preliminary results from first BEAT. ASCO Gastrointestinal Cancer Symposia 2006. San Francisco, CA; January 26-28, 2006. p. 245 (Abstract).
27. A Grothey, et al. 2007 Association between exposure to bevacizumab beyond first progression and overall survival in patients with metastatic colorectal cancer: Results from a large observational study (BRiTE) Proc Am Soc Clin Oncol 172s 4036 (Abstract)
28. L Saltz, et al. 2007 Bevacizumab in combination with XELOX or FOLFOX: Updated efficacy results from XELOX-1/N016966, a randomized phase III trial in first line metastatic colorectal cancer Proc Am Soc Clin Oncol 170s 4028 (Abstract)
29. K Barnard 2006 Viewpoint: an explanation for the cardiovascular effects of bevacizumab and rofecoxib? Circulation 114 19 f173 f175 17088471
30. I Zachary A Mathur S Yla-Herttuala J Martin 2000 Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor Arterioscler Thromb Vasc Biol 20 6 1512 1520 10845866 1:CAS:528: DC%2BD3cXksVCgtrc%3D
31. NN Nissen, et al. 1998 Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing Am J Pathol 152 6 1445 1452 9626049 1:CAS:528:DyaK1cXktVSkurY%3D